Terrier B, et al. - Experts sought to compare long-term effectiveness of remission-maintenance regimens in patients with newly diagnosed or relapsing antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides. As per data, a superior rate of sustained remission for ANCA-associated vasculitis patients, after rituximab-based or azathioprine-based maintenance regimens over 60 months with rituximab, with better overall survival was seen. An independent association of antiproteinase-3-ANCA positivity and azathioprine arm with a higher risk of relapse was seen. Over time, HRs of positive ANCA to predict relapse increased.